Oscient Pharmaceuticals is a biopharmaceutical company committed to the clinical development and commercialization of new therapeutics to serve unmet medical needs. Oscient's product portfolio is now led by the Food and Drug Administration-approved fluoroquinolone antibiotic FACTIVE (gemifloxacin mesylate) tablets, indicated for the treatment of community-acquired pneumonia of mild-to-moderate severity and acute bacterial exacerbations of chronic bronchitis. The Company's Ramoplanin is in clinical trials for the prevention and treatment of serious hospital-acquired infections. Ramoplanin is in a Phase III trial for the prevention of bloodstream infections caused by vancomycin-resistant enterococci and in a Phase II trial for the treatment of Clostridium difficile-associated diarrhea.